Pfizer Reiterates Commitment to Pandemic Preparedness
NEW YORK, NY, MAY 28, 2024 – Pfizer Inc. (NYSE:PFE) continues to closely monitor all developments regarding the circulation and outbreaks of the A/H5N1 virus.
Fostering Neurodiversity: A Pfizer Panel Discussion
At Pfizer, we are dedicated to fostering a diverse and inclusive workplace where every individual feels valued and respected. As part of this commitment, our Disability Colleague Resource Group launched the Neurodiversity Colleague Community during Neurodiversity Celebration Week in March to ensure that we are inclusive of our colleagues who navigate neurodiversity, including those who are caregivers.
Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection Carpuject™ Units and Labetalol Hydrochloride Injection, USP Carpuject™ Units Due To The Potential For Incomplete Crimp Seals
FOR IMMEDIATE RELEASE – May 21, 2024 - NEW YORK, NY.,
Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units to the User level. The recall was initiated due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit.
April Social Media Round-Up—Black Maternal Health, World Immunization, and Long Covid
Pfizer jumped into spring with another busy month on social media.
Pfizer Goes Live in SXSW’s Podcast Lounge
For more than a quarter of a century, SXSW has been a must-do event on the calendars of consumers, celebrities, and cognoscenti. Part conference, part festival, it’s where people gather to learn about the latest trends in tech, media, and entertainment.
March Social Media Round-Up—Annual Review, International Women’s Day, and a School of Science Celebration
March is an eventful month, with the launch of spring, the changing of the clocks, St. Patrick’s Day, and more. Here at Pfizer, we had plenty occasions to mark, and all month long our leadership did just that, sharing their thoughts on International Women’s Day and Employee Appreciation Day, celebrating the anniversary of our School of Science, and looking back at our recent accomplishments with the publication of our Annual Review.
Working to “Outdo” Cancer: A Multi-Modality Approach to Accelerating the Next Generation of Cancer Breakthroughs
If you caught Pfizer’s exciting commercial that ran during the NFL’s big game in February, you know that we are making a renewed commitment to outdo cancer – nothing is more urgent, or more personal, than our goal to outpace, outsmart, and outmaneuver cancer at every turn.
Pfizer Receives Positive CHMP Opinion for its Novel Antibiotic Combination for the Treatment of Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, March 22, 2024 – Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for EMBLAVEO® (aztreonam-avibactam) in the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
Pfizer Celebrates Legacy, Justice, and Equity
Pfizer colleagues reflected on the significance of the Martin Luther King, Jr holiday and Black History Month with a series of events organized by members of Pfizer’s Global Black Community (GBC).
2023 In Review
At Pfizer, we are working tirelessly to outdo yesterday by bringing new breakthroughs to patients around the globe in innovative ways. As we do this, it’s important that we take the time to reflect on both our challenges and our achievements.